On 31 Jan 2016 Canaccord issued a review of AXP that stated unit sales in the US for 2017 would be 12,810 (I remember in my analysis I used 25% of Canaccord lagged by a year); not a Management forecast!
On 25 September 2016 they had US unit sales in 2017 of 3,202; again not a Management forecast!
On 29 Jan 2017 they had unit sales of 3004 units.
In late April, as part of their 4C commentary, Scott Dodson said Management expected sales "to measured in dozens of units in 1H17, hundreds of units in the middle of the year and thousands of units by the end of the year"; this is a Management forecast!
The real SP weakness started on May 25!!
..lower growth pathway...hmmmm ... doesn't stack up!!
Ann: Update on AeroForm Availability in US Medical Institutions, page-7
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AXP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.824M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $4.303K | 2.151M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 40085905 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 91807222 | 63 |
View Market Depth
| Last trade - 10.57am 04/12/2024 (20 minute delay) ? |
| AXP (ASX) Chart |
